{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.4"},{"groupId":"OG001","value":"10.0"},{"groupId":"OG002","value":"8.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1908"},{"groupId":"OG001","value":"660"},{"groupId":"OG002","value":"463"}],"units":"Participants"}],"description":"Participants collected their oral body temperature in the evening of their vaccination day and at the same time each day thereafter for 4 days. The maximum body temperature obtained within 5 days of any of the 3 vaccinations was recorded. The percentage of participants who had at least 1 oral body temperature reading that was ≥100.0°F (≥37.8ºC) was summarized.","groups":[{"description":"Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.","id":"OG000","title":"9- to 15-Year-Old Females (Lots 1, 2, or 3)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.","id":"OG001","title":"Base Study: 9- to 15-Year-Old Males (Lot 1)"},{"description":"9vHPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered was obtained from manufacturing Lot 1.","id":"OG002","title":"Base Study: 16- to 26-Year-Old Females (Lot 1)"}],"paramType":"NUMBER","populationDescription":"All participants who received at least one dose of 9vHPV vaccine and had available follow-up data. Per protocol, this outcome measure included data from 9- to 15-year-old females regardless of lot administered.","reportingStatus":"POSTED","timeFrame":"Up to 5 days after any vaccination","title":"Base Study: Percentage of Participants With Body Temperature ≥100.0°F (≥37.8ºC)","type":"PRIMARY","unitOfMeasure":"Percentage of Participants"}